4.6.3. Conclusion
The objective of this study was to assess the effect and the mechanism of action of prokidin (a chromone compound found naturally as one of the ingredients of aloe) in terms of reducing cisplatin nephrotoxicity. The results indicated that prokidin was by far the most effective suppressant of cisplatin nephrotoxicity. The optimal cisplatin dosage was found to be 3 doses of 60mg/kg each and the optimal timing to be 72, 48 and 24 hours before cisplatin administration. The absence of any deleterious influence on cisplatin’s anti-cancer effect was also confirmed. The mechanism of nephrotoxicity suppression was by way of its effect on the neutrophil function of the renal blood. It stimulated the neutrophils to discharge oxygen radicals, thus preventing them from damaging organs. Based on these findings, we are of the view that prokidin has potential as a drug for reducing cisplatin-induced nephrotoxicity. However, successful efficacy trials with human subjects are required before it can be considered for clinical use.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Alan MJ (1984) Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy. Ann. Int. Med., 101, 41–44
David DC, Daniel SL (1981) Anthony, A, Acute and chronic cisplatin nephropathy in rats. Lab Kid 44, 397–402
Dennis CD, Joseph L, Charlotte J, Jon K, Michael WW (1980) Mechanism of cis-platinum nephrotoxicity; II. Morphologic observations. J. Pharmacol. Exp Ther 213; 551–556
Dufour P, Bergerat JP, Eber M, Renayd P, Karcher V, Giron C, Leroy MJ Oberling F (1990) Cisplatin-induced acemia; A potential interference with iron metabolism at erythroid progenitors leved. 1; 49–54
Ellerby RA, Davis HL Jr, Ansfield FJ (1974) Phase I clinical trial of combined therapy with 5-FU (NSC-19893) and cis-platinum(II) diamminedichloride(NSC-119875). Cancer 34; 1005–1010
Hook JB, McCormack M, Kluwe WM (1979) Biochemical mechanisms of nephrotoxicity. Rev. Biochem. Toxicol 1; 53–78
Hook JB, Hewitt WR (1986) Toxic responses of the kidney. In: Klaassen, C.D, Amdur, M.O. and Doull, J. (Eds.), Casarett and Doull’s Toxicology, The Basic Science of Poisons, 3rd Edn., MAcmillan New York 310–329
Jon DB, Julian BH (1981) Renal and electolyte disturbances associated with cisplatin Ann Int Med 95; 628–632
Jon DB, Julian BH (1981) Renal and electolyte disturbances associated with cisplatin Ann Int Med 95; 628–632
Juan CG, Daniel MH, Esteban C, Stephen SS (1977) The renal pathology in clinical trials of cis-platin ciamminedichloride Cancer 39; 1362–1371
Kamalakar P, Wang JJ, Higby D (1976) Clinical Experience with cis-diamminedichloroplatinum(DDP) in chidren Proc Am Assoc Cancer Res Proc Am Soc Clin Oncol 17; 283
Kovach JS, Moertel CG, Schutt AJ (1973) Phase II study of cis-diamminedichloroplatinum (NSC-119875) in advanced carcinoma of the large bowel Cancer Chemother Rep 57; 357–359
Lippman AJ, Helson C, Helson L (1973) Clinical trials of cis-diamminedichloroplstinum (II)(NSC-119875). Cancer Chemother Rep 57; 191–200
Nicolas EM, John TH (1978) Platinum nephrotoxicity Am J Med 65; 307–314
Piel IJ, Meyer D, Perlia CP (1974) Effects of cis-diamminedichloroplatinum(NSC-119875) on hearing function in man. Cancer Chemother Rep 58; 871–875
Robert S, Peter M, Joseph BG (1984) Uptake and metabolism of cisplatin by rat kidney Kid Int 25; 753–758
Robin SG, Gilbert HM (1983) The nephrotoxicity of cisplatin Life Sciences 32; 685–690
Ronald CD, Bartlett RT, Robert CL, William AC (1973) Clinical and pharmacological studies with cis-diamminedichloroplatinum(NSC-119875). 33, 1310–1315
Rosenerg ML, Holoye PY, Johnson DE (1975) Bleomycin combination chemotherapy in the management of testicular neoplasia Cancer 36; 318–356
Rush GF, Smith JH, Newton JF, Hook JB (1984) Chemically induced nephrotoxicity; role of metabolic activation. CRC crit Rev Toxicol 13; 99–160
Samuels ML, Holoye PY, Johnson DE (1975) Bleomycin combination chemotherapy in the management of testicular neoplasia Cancer 36; 318–356
Sartori S, Nielsen I, Masotti M, Malacarne P (1991) Early and late hyperferremia during cisplatin chemotherapy J Chemo 3; 45–50
Walter GG, Brian DR (1984) Enzyme distribution along the nephron Kid Int 26; 101–111
Wittes RE, Brescia F, Young CW (1975) Combination chemotherapy with neck Oncology 32; 202–207
Yagoda A, Watson RC, Whitmore WF (1977) Adriamycin in advanced urinary tract cancer; Experiene in 42 patients and review of the literature Cancer 39; 279–285
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Choung, S.Y. (2006). Protective effect on nephrotoxicity. In: Park, Y.I., Lee, S.K. (eds) New Perspectives on Aloe. Springer, Boston, MA . https://doi.org/10.1007/0-387-34636-8_11
Download citation
DOI: https://doi.org/10.1007/0-387-34636-8_11
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-31799-1
Online ISBN: 978-0-387-34636-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)